Q2 2026 revenue rose 11% year-over-year to $201.7M, led by 14% clinical growth and 26% NGS growth. Gross margin expanded 260 bps, and adjusted EBITDA grew 36%. Full-year guidance was raised, with continued investment in high-value testing and operational efficiency.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.